Analyst target prices moved sharply on Thursday, with consumer names bearing the brunt of downgrades while pharma stocks attracted upgrades.
Clorox saw the steepest consensus target cut. Analysts trimmed their average price target to $109.06, down from $115.47. That's a drop of over $6 in one session. The household goods maker carries 7.5% short interest as a percentage of free float, suggesting bears remain active.
ResMed also lost ground with analysts. The consensus target fell to $273.40 from $288.21. That's a 5.1% slide. The medical device firm's $31 billion market cap makes the cut especially notable.
On the bullish side, AbbVie drew fresh support. The consensus target edged up to $250.33 from $250.03. The pharma giant's short interest sits at just 1.2% of free float — few bears willing to fight it.
Apple also got a lift. Analysts nudged their average target to $301.36, up from $298.46. That keeps the consensus firmly above $300.
Martin Marietta Materials bucked the materials trend with a small downgrade in consensus. The target slipped to $691.48 from $692.04. Minor in percentage terms, but still directionally negative.
This is not financial advice.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
